Biological
LP-003 clinical trials
Also written LP-003.
- studies test it
- 10
- open now
- 4
- in phase 3
- 1
- first study started
- 2022
Keep track of what changes. Save the LP-003 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses LP-003 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat AllergyNot yet recruitingPhase 2Longbio Pharma (Suzhou) Co., Ltd.NCT07816432Written as LP-003 Injection
- Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic PatientsNot yet recruitingPhase 2Longbio Pharma (Suzhou) Co., Ltd.NCT07785063Written as LP-003 Injection
- A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Not yet recruitingPhase 2Longbio PharmaNCT07313917Written as LP-003 Injection
- Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma PatientsRecruitingPhase 2Longbio PharmaNCT07342803Written as LP-003 Injection
- Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedPhase 2Longbio PharmaNCT06228560Written as LP-003
- A Study of Single Dose of LP-003 in Adolescent SubjectsActive, not recruitingPhase 1/2Longbio PharmaNCT07148557Written as LP-003 Dose 1 (Single)
- Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic RhinitisActive, not recruitingPhase 3Longbio PharmaNCT07291284Written as LP-003
- A Study of Single Dose of LP-003 in Healthy Adult SubjectsActive, not recruitingPhase 1Longbio PharmaNCT06604949Written as LP-003 200mg
- Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis AdultCompletedPhase 2Longbio PharmaNCT06046391Written as LP-003 dose 1
- A Study of Single and Multiple Doses of LP-003 in Healthy Adult ParticipantsCompletedPhase 1Longbio PharmaNCT06294288Written as LP-003 Dose 1 (Single)